IndiaTickerLatest filing: Cipla Ltd - 500087 - Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
ObservedCompany dossier
Cipla
NSE:CIPLA · ISIN INE059A01026
- Close
- ₹1,474.3 29 Jul 2026
- Daily change
- N/A Exchange close
- Evidence state
- Building 0/0 checks
Cipla
Overview
Evidence state
Coverage in progressCompany record at a glance
Latest reported period: 30 Jun 2026 · revenue N/A · PAT N/A.
Exchange XBRLLatest ownership: promoter group 29.21% and public 70.79% as of 30 Jun 2026.
Exchange XBRLMaterial events
Open timeline →What changed recently
Observed
Source filing Cipla Ltd - 500087 - Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
BSE · exchange filing
Observed
Source filing Updates - Cipla Limited
NSE · exchange filing
Observed
Source filing Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
BSE · conference call
Observed
Source filing Analysts/Institutional Investor Meet/Con. Call Updates - Cipla Limited
NSE · conference call
Reported financials
Full financials →30 Jun 2026
- Revenue from operations
- N/A
- Profit after tax
- N/A
- EPS
- N/A
Observed BSE structured filing · consolidated
Ownership
Full shareholding →30 Jun 2026
- Promoter group
- 29.21%
- Public
- 70.79%
- Employee trust
- 0.00%
Observed NSE shareholding XBRL